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Research
Hypertension is a major risk factor for future 
cardiovascular disease (Chobanian et al. 
2003; Greenlund et al. 2004). It has also been 
demonstrated that elevated blood pressures 
(between normal and clinically hypertensive) 
are indicative of increased cardiovascular risk 
(Kshirsagar et al. 2006). Pregnancy poses 
additional risks from high blood pressure. 
Hypertension occurring during pregnancy 
may lead to preeclampsia, a serious condi-
tion associated with substantial maternal and 
fetal morbidity and mortality (Solomon and 
Seely 2006). Hypertension during pregnancy 
may also predispose women to development 
or increased severity of future cardiovascular 
disease (Garovic and Hayman 2007; Moreira 
et al. 2009).
Well-established risk factors for hyper-
tension include age, race, obesity, diet, 
and family history (Whelton et al. 2002). 
Primiparity and multiple gestations are addi-
tional risk factors for gestational hyperten-
sion (GH) and preeclampsia (Solomon and 
Seely 2006). In addition, there is evidence 
that lead exposure in adults is a risk factor 
for elevated blood pressure (Navas-Acien 
et al. 2007; Nawrot et al. 2002). Lead has 
also been associated with GH (Chen et al. 
2006; Magri et al. 2003; Rabinowitz et al. 
1987; Rothenberg et al. 2002; Vigeh et al. 
2004; Yazbeck et al. 2009) and/or preeclamp-
sia (Dawson et al. 2000; Sowers et al. 2002; 
Vigeh et al. 2006), as well as elevated blood 
pressure (Magri et al. 2003; Rabinowitz et al. 
1987; Rothenberg et al. 1999, 2002).
However, most of these studies were con-
ducted in populations with lead levels sub-
stantially higher than current levels in the 
United States and other developed countries, 
where blood lead levels in all age groups have 
markedly declined primarily due to the ban-
ning of lead in gasoline and other regula-
tory actions initiated to limit lead exposure 
[Centers for Disease Control and Prevention 
(CDC) 2009; Meyer et al. 2003]. Recent evi-
dence demonstrates that despite this general 
decline in population lead exposure, higher 
lead blood levels remain positively associated 
with hypertension, particularly among adult 
African Americans and Mexican Americans 
(Muntner et al. 2005). Yazbeck et al. (2009) 
have shown that low blood lead concentra-
tions are related to GH. The goal of the pres-
ent study was to evaluate the relationship of 
lead as measured in umbilical cord blood with 
maternal blood pressure during pregnancy, 
within the Baltimore Tracking Health Related 
to Environmental Exposures (THREE) Study.
Methods
Study population. We performed a cross-
  sectional study of 285 births from the 
Baltimore THREE Study. Details about 
this study have been published previously 
(Apelberg et al. 2007). This study had the 
approval of the Maternal and Fetal Research 
Committee, Department of Gynecology and 
Obstetrics, and the Johns Hopkins School of 
Medicine Institutional Review Board (IRB). 
We obtained a Health Insurance Portability 
and Accountability Act waiver. The IRB 
waived the requirement for informed con-
sent because the collected biological samples 
would otherwise have been discarded and the 
sample collection constituted no more than 
minimal risk to the subjects. Strict procedures 
protected subject confidentiality, and all data 
and specimens were anonymized.
There were 615 births (603 deliver-
ies) between November 2004 and March 
2005. Of these, we excluded multiple births 
(n = 24 infants) and births where cord blood 
was unavailable or of insufficient quantity 
(n = 291), leaving a total of 300 births eli-
gible for the study. These are representative 
of all births at the hospital, except that there 
were fewer low-birth-weight infants because 
smaller babies tended to have less cord blood. 
Fifteen infants had missing data for key vari-
ables (n = 13) or for having outlying data 
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Ba c k g r o u n d: Lead exposure is associated with elevated blood pressure during pregnancy; however, 
the magnitude of this relationship at low exposure levels is unclear.
oBjectives: Our goal was to determine the association between low-level lead exposure and blood 
pressure during late pregnancy.
Me t h o d s : We collected admission and maximum (based on systolic) blood pressures during labor 
and delivery among 285 women in Baltimore, Maryland. We measured umbilical cord blood lead 
using inductively coupled plasma mass spectrometry. Multivariable models were adjusted for age, 
race, median household income, parity, smoking during pregnancy, prepregnancy body mass index, 
and anemia. These models were used to calculate benchmark dose values. 
re s u l t s: Geometric mean cord blood lead was 0.66 µg/dL (95% confidence interval, 0.61–0.70). 
Comparing blood pressure measurements between those in the highest and those in the lowest 
quartile of lead exposure, we observed a 6.87-mmHg (1.51–12.21 mmHg) increase in admission 
systolic blood pressure and a 4.40-mmHg (0.21–8.59 mmHg) increase in admission diastolic blood 
pressure after adjustment for confounders. Corresponding values for maximum blood pressure 
increase were 7.72 (1.83–13.60) and 8.33 (1.14–15.53) mmHg. Benchmark dose lower limit values 
for a 1-SD increase in blood pressure were < 2 µg/dL blood lead for all blood pressure end points.
co n c l u s i o n s: A significant association between low-level lead exposures and elevations in maternal 
blood pressure during labor and delivery can be observed at umbilical blood lead levels < 2 µg/dL.
key w o r d s : benchmark dose, blood pressure, hypertension, lead, pregnancy, risk assessment, 
umbilical cord. Environ Health Perspect 119:664–669 (2011).  doi:10.1289/ehp.1002666 [Online 
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(n = 2), and we excluded them from analyses. 
The two outliers included one subject with 
an admission systolic blood pressure (SBP) 
< 20 mmHg (likely due to measurement or 
recording error) and one with an umbilical 
cord blood lead value of 15.5 µg/dL (more 
than two times higher than the second largest 
value). Sensitivity analyses confirmed that the 
exclusion of the lead outlier did not substan-
tially alter results.
Data collection. Two study personnel col-
lected data from maternal medical records. 
Study clinicians reviewed a 10% random 
sample for accuracy.
Blood pressure end points. From the 
medical record we collected diagnoses of GH, 
preeclampsia, chronic hypertension, and use 
of antihypertensive medications. We created 
two variables to summarize these: a) those 
with GH or preeclampsia versus not, and 
b) those with GH, preeclampsia, or chronic 
hypertension or used hypertensive medications 
(referred to as “any hypertension”) versus not. 
Hospital personnel measured maternal blood 
pressure at admission for labor and delivery 
and continuously during hospitalization using 
a General Electric Corometrics model 120 
series fetal monitor (GE Healthcare, Little 
Chalfont, UK), which uses a noninvasive 
blood pressure measurement based on the 
DINAMAP algorithm. The monitor meas-
ured blood pressure at programmed inter-
vals ranging from once per minute to once 
per hour, depending on clinical needs. The 
varying time intervals, combined with the 
fact that women were in the hospital for 
varying amounts of time, resulted in large 
variability in the quantity and frequency of 
available measurements. We recorded three 
pairs of blood pressure measurements from 
each mother: SBP and diastolic blood pres-
sure (DBP) at admission, the maximum SBP 
and corresponding DBP, and the minimum 
SBP and corresponding DBP. We compared 
these measurements with relevant charac-
teristics from the medical record to validate 
their utility. Blood pressure measurements 
were not related to the time of day of hos-
pital admission. Those with a hypertension 
diagnosis or using antihypertensive medica-
tions had higher admission and maximum 
blood pressure measurements than did moth-
ers without any hypertension (Student’s t-test, 
p < 0.05). Minimum blood pressure was only 
weakly associated with measures of hyper-
tension and was also the only blood pressure 
measurement significantly related to length of 
labor and type of delivery [Spearman correla-
tion, p < 0.05; one-way analysis of variance 
(ANOVA), p < 0.05, respectively]. Moreover, 
our observations suggest that minimum blood 
pressure measurements may be influenced 
by events during labor and delivery such as 
a blood pressure cuff being too loose for an 
accurate measurement or use of pain reduc-
tion medication and therefore were not used 
in analysis.
Umbilical cord blood collection and lead 
measurements. Trained clinical staff used a 
well-defined method to collect umbilical cord 
blood immediately after the cord was cut 
(Witter et al. 2001). After temporary storage 
(< 3 hr) at 4°C, we transferred 0.5 mL ali-
quots of whole blood to 2 mL polypropylene 
containers; to obtain serum we centrifuged 
blood collected in red top tubes. CDC labo-
ratories determined that specimen containers 
and syringes were lead free before the study. 
We stored anonymized frozen samples at 
–80°C except during transport in dry ice.
The CDC laboratories measured lead in 
whole blood using inductively coupled plasma 
mass spectrometry. This method has high 
accuracy and sensitivity with a limit of detec-
tion (LOD) of 0.25 µg/dL. Thirteen samples 
(4.6%) were below the LOD, which were 
replaced with LOD/√
– 2 for analyses. Because 
lead is readily transferred across the placental 
barrier, umbilical cord blood lead and mater-
nal venous blood lead are highly correlated 
(Chuang et al. 2001), and cord blood lead 
levels can serve as a proxy measure for mater-
nal blood lead levels in epidemiologic studies 
(Rabinowitz et al. 1987). CDC laboratories 
also measured cotinine in cord serum using 
liquid chromatography in conjunction with 
atmospheric pressure ionization mass spec-
trometry (LOD = 0.015 ng/mL) (Bernert et al. 
1997). We classified a mother as a smoker if 
cord serum cotinine was ≥ 10 ng/mL (Pirkle 
et al. 1996) or if the medical record stated that 
she smoked at any time during pregnancy.
Additional variables. We calculated 
prepregnancy body mass index (BMI) from 
prepregnancy weight and height recorded in 
the maternal medical record. For mothers 
with missing height (n = 6), prepregnancy 
weight (n = 3), or both (n = 1), we imputed 
values using regression models incorporating 
placental weight, weight gain during preg-
nancy, race, education, prepregnancy weight, 
and height. We also explored use of median 
imputation; results were similar to the multi-
variable regression (data not shown). Maternal 
medical records were also the source of infor-
mation for maternal age, length of gestation, 
parity, anemia, and type of medical insurance.
For household income, we used U.S. 
Census 2000 median household income at the 
block group level. A block group was a sub-
division of a census tract in which optimally 
1,500 people reside but may range from 300 
to 3,000. GeoLytics, Inc. (East Brunswick, 
NJ) matched 91% of maternal residences to 
block groups; we geocoded the remaining 
addresses using TerraServer USA (Microsoft 
Corporation, Redmond, WA) or ArcMap 9.0 
with StreetMap 2000 (ESRI, Redlands, CA).
Data analysis. We used Stata 9.3 (StataCorp 
LP, College Station, TX) for descriptive and 
multivariable regression analyses. A p-value 
< 0.05 was considered statistically significant. 
We used descriptive statistics to inform our 
unadjusted and adjusted multivariable regres-
sion analyses. Geometric means and 95% con-
fidence intervals (CIs) are presented for lead 
because it has a log-normal distribution.
We evaluated several dose–response func-
tions to describe the relationship of cord blood 
lead levels and blood pressure measures. We 
modeled lead as categorical, linear, logarithmic 
(natural), quadratic, and as a cubic spline. We 
compared these by examining lowess (non-
parametric) smoothing curves, Akaike’s infor-
mation criterion (AIC), Bayesian information 
criterion, adjusted R2 (or pseudo-R2) values, 
and root mean squared error. We selected lead 
quartiles as the model of choice. This option 
had a similar goodness of fit and has the added 
benefit of not limiting the exposure–outcome 
relationship to a specific form. Tests for trend 
are based on the p-value for the lead variable 
categorized into quartiles.
We evaluated additional variables for inclu-
sion based on previous knowledge (Nawrot 
et al. 2002; Rothenberg et al. 2002) or because 
of associations with blood pressure measures 
and/or lead levels within this particular data set. 
These included maternal age, education, race, 
prepregnancy BMI, reported alcohol use dur-
ing pregnancy, smoking status, parity, marital 
status, medical insurance type, neighborhood 
median household income, neighborhood per 
capita income, anemia, and gestational age. 
No relationship of umbilical cord blood lead 
with gestational age was evident in this data set 
(Spearman’s ρ = 0.04, p = 0.49).
We tested model assumptions and fit using 
quartile–quartile plots and residual versus fitted 
value plots. We performed sensitivity analyses 
to evaluate the effect of excluding the influen-
tial lead value (cord blood lead > 15 µg/dL) 
and the inclusion of imputed BMI values (data 
not shown). We assessed the possibility of effect 
modification with lead and BMI, maternal age, 
maternal race, or per capita income levels and 
saw no evidence of such effects.
To interpret results in a risk assessment 
context, we estimated benchmark dose (BMD) 
and the BMD lower confidence limit (BMDL) 
for the effect of lead exposure on maternal 
blood pressure using Benchmark Dose Software 
[version 2.1; developed by Lockheed Martin 
Corp. for the U.S. Environmental Protection 
Agency (U.S. EPA 2011)]. The BMD is an 
exposure level at which one observes a pre-
specified amount of response [e.g., the bench-
mark response (BMR)] in a population. The 
BMR (a health outcome) is typically a 5% or 
a 10% change in incidence (for dichotomous 
responses) or a 1-SD change in response (for 
continuous responses) compared with control Wells et al.
666  v o l u m e  119 | n u m b e r 5 | May 2011  •  Environmental Health Perspectives
individuals (U.S. EPA 2000). In this study, 
“control” individuals were defined as those 
with lead measurements in the lowest exposure 
quartile. The BMDL is the one-sided lower 
95% confidence limit, equivalent to a 90% 
two-sided confidence limit. Currently, BMDLs 
are used by the U.S. EPA in some contexts 
as a point of departure for a risk assessment, 
in which uncertainty factors are added to 
calculate a regulatory or guidance level. This 
approach, and how it is an improvement over 
prior techniques, has been well described (Sand 
et al. 2008). One advantage of using such an 
approach for a substance such as lead is that, 
unlike a no observable adverse effect level 
(NOAEL), no assumption of a threshold for 
effects is required. However, this technique 
also has some drawbacks, including that for 
some outcomes it may be difficult to identify 
an appropriate critical effect size (e.g., BMR) 
(Dekkers et al. 2001; Travis et al. 2005) and 
for some data sets it is not possible to fit a 
BMD model (Travis et al. 2005).
Although originally designed to be used 
with toxicologic data, BMD methods have 
also been used with epidemiologic data 
(Budtz-Jorgensen et al. 2001). The most cur-
rent version of the Benchmark Dose Software, 
however, does not yet allow for multivari-
able model fitting. Because several important 
risk factors other than lead exposure influ-
ence blood pressure levels, our BMD mod-
els incorporated these potential confounders 
by using adjusted blood pressure measure-
ments obtained from our multivariate mod-
els (described above). We derived these by 
using linear combinations of model covariates 
(Stata’s lincom command), where we set each 
covariate to the study population mean. Our 
BMD models then consisted of lead quartiles 
as the exposure and adjusted maternal blood 
pressure as the response.
We used standard methods for determin-
ing a BMD (U.S. EPA 2000). The BMR was 
an increase of 1 SD of blood pressure from the 
blood pressure level among “controls” (those 
in the lowest quartile of umbilical cord lead 
concentrations). The 1-SD change generally 
approximates a 10% change (Crump 2002). 
We used the program’s default values for all 
other model parameters. We ran several differ-
ent types of models (Hill, linear, polynomial, 
and power) and evaluated model fit using AIC 
and visual inspection.
Results
Age at delivery ranged from 14 to 43 (mean 
= 26) years. There were 70.9% African 
Americans, 20.7% Caucasians, and 8.4% 
Asians. Fifty-four women (19.0%) were 
active smokers during pregnancy. Almost 
half (49.8%) were overweight or obese before 
pregnancy. In bivariate comparisons, lead 
levels were higher among Asians and African 
Americans compared with Caucasians, those 
living in neighborhood with a median income 
of < US$25,000 per year versus not, multi-
parous women, and those who smoked during 
pregnancy (Table 1).
At admission, mean SBP was 121.8 mmHg 
(95% CI, 119.9–123.7), mean DBP was 
71.8 mmHg (70.4–73.1), maximum SBP was 
144.3 mmHg (142.2–146.3), and maximum 
DBP was 77.4 mmHg (75.1–79.7). Sixteen 
women (5.6%) had GH or preeclampsia, and 
27 women (9.5%) had any hypertensive con-
dition. The geometric mean cord blood lead 
was 0.66 µg/dL (0.61–0.71 µg/dL), and the 
highest quartile for lead was 0.96–6.47 µg/dL.
We observed no increase in the odds of 
GH or preeclampsia or any hypertension 
related to increasing lead exposure levels (data 
not shown). However, mothers in the high-
est lead quartile had a statistically significant 
increase in admission and maximum SBP 
and DBP during labor and delivery com-
pared with those in the lowest quartile, after 
adjusting for maternal age, maternal race, 
neighborhood median household income, 
prima  parity, smoking during pregnancy, 
prepregnancy BMI, and anemia (Table 2). 
Specifically, we observed a 6.87-mmHg 
(95% CI, 1.51–12.21) increase in SBP and 
a 4.40-mmHg (0.21–8.59) increase in DBP 
admission blood pressure comparing the high-
est and lowest lead quartiles. Corresponding 
increases in maximum blood pressure were 
7.72 mmHg (1.83–13.60) for SBP and 
8.33 mmHg (1.14–15.53) for DBP.
We defined our BMR as a 1-SD increase 
in blood pressure; this was from 11.9 to 
20.4 mmHg for all blood pressure out-
comes. In comparing different types of BMD 
models, the power BMD models provided 
the best fit for the blood pressure measures 
overall (Table 3). Using this model, BMDs 
(BMDLs) were 1.46 µg/dL (1.42) for admis-
sion SBP, 1.91 µg/dL (1.43) for admission 
DBP, 1.45 µg/dL (1.41) for maximum SBP, 
and 1.47 µg/dL (1.43) for maximum DBP.
Table 1. Geometric mean and 95% CIs for umbilical cord lead concentrations (μg/dL) by population 
charac  teristics: Baltimore THREE Study, 2004–2005 (n = 285).
Characteristic n Geometric mean 95% CI
All mothers 285 0.66 0.61–0.70
Age, years
< 20 58 0.72 0.64–0.81
20–30 134 0.64 0.57–0.71
> 30 93 0.64 0.56–0.73
Race
Caucasian 59 0.44* 0.38–0.52
Asian 24 0.85* 0.67–1.09
African American 202 0.72* 0.66–0.77
Median household income (US$)
< 25,000 89 0.81* 0.71–0.92
25,000–50,000 151 0.64* 0.59–0.70
> 50,000 45 0.55* 0.50–0.61
Parity
Primiparous 118 0.61* 0.55–0.67
Multiparous 167 0.69* 0.63–0.76
Smoking
Nonsmoker 231 0.61* 0.57–0.67
Active smoker 54 0.83* 0.71–0.97
Prepregnancy BMI (kg/m2)
< 18.5 14 0.58 0.42–0.80
18.5–24.9 129 0.63 0.57–0.70
25.0–29.9 71 0.66 0.57–0.76
≥ 30 71 0.72 0.62–0.82
Anemia
Not anemic 249 0.65 0.60–0.70
Anemic 36 0.69 0.58–0.80
Admission SBP (mmHg)
< 140 252 0.65 0.60–0.70
≥ 140 33 0.73 0.60–0.89
Admission DBP (mmHg)
< 90 265 0.65 0.60–0.70
≥ 90 20 0.74 0.60–0.91
Maximum SBP (mmHg)
< 140 123 0.60* 0.54–0.67
≥ 140 162 0.70* 0.63–0.77
Maximum DBP (mmHg)
< 90 229 0.63* 0.58–0.68
≥ 90 56 0.78* 0.67–0.92
*Statistically significant difference in geometric mean lead levels across categories, p < 0.05, one-way ANOVA or 
Student’s t-test. Lead and blood pressure during pregnancy
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Discussion
In this study we found a modest but signifi-
cant association between very small increases 
in umbilical cord blood lead and elevations 
in SBP and DBP during labor and delivery. 
This association was observed at blood lead 
concentrations well below the current CDC 
recommended action level of 10 µg/dL for 
children and below the recommended level of 
5 µg/dL for pregnant women (CDC 2007). 
Average blood lead concentrations in this 
study are lower than in prior studies of lead 
and blood pressure in pregnant women with 
the exception of the EDEN cohort study 
(Yazbeck et al. 2009).
Our findings are consistent with previ-
ous studies on blood lead levels and blood 
pressure during pregnancy (Magri et al. 
2003; Rabinowitz et al. 1987; Rothenberg 
et al. 1999, 2002). Unlike other studies (Chen 
et al. 2006; Dawson et al. 2000; Magri et al. 
2003; Sowers et al. 2002), we did not observe 
an association between lead and GH, pre-
eclampsia, or clinically diagnosed hyperten-
sion as noted in the medical record. Except for 
that of Rabinowitz et al. (1987), these studies 
differed from ours in that they used maternal 
venous blood lead measurements and blood 
pressure taken before labor and delivery. Our 
measurements, blood pressure during labor 
and delivery as well as umbilical cord blood 
lead concentrations, have some limitations (as 
discussed below) but may still represent the 
relative lead exposure and blood pressure sta-
tus of these women.
Studies of blood pressure customarily use 
the average of three measurements on a seated, 
resting subject. We did not collect, and there-
fore could not average, multiple blood pres-
sure measurements for each individual; this 
may have introduced some nondifferential 
misclassification, which would be expected to 
attenuate results. Additionally, in our study, 
like Rabinowitz et al. (1987), we used blood 
pressure measurements taken during labor and 
delivery, a time of additional stress. Our blood 
pressure measures are therefore not equivalent 
to the standardized measures that one would 
obtain in a more controlled setting. However, 
because all of our blood pressure measures 
were taken during similar conditions for all 
women, they are likely to be similarly skewed. 
Supporting the validity of our blood pressure 
measures, women with previous hyper  tension 
diagnosis during or before pregnancy had 
higher admission and maximum blood pres-
sure levels, and neither admission nor maxi-
mum pressures were correlated with the length 
of the hospital stay.
An important strength of this study was 
the quality of cord blood exposure measure-
ments. Through obtaining clean samples 
and our use of high-quality analytic meth-
ods, we were able to obtain quantitative lead 
measurements for most of this population, 
despite the fact that their lead exposures 
were very low. Because of constraints of the 
study design, we were unable to measure 
maternal blood lead levels. Umbilical cord 
metal measurements, however, may serve as a 
proxy for maternal exposure. Indeed, umbili-
cal cord blood lead is highly correlated with 
maternal venous blood lead [reported at r2 
= 0.82 (Chuang et al. 2001)]; thus, use of 
cord blood lead will reasonably differentiate 
among different blood lead concentrations 
among mothers. Recognizing this, previ-
ous studies have also used cord blood lead to 
evaluate associations with maternal hyperten-
sion or preeclampsia (Rabinowitz et al. 1987; 
Vigeh et al. 2006). Several investigators report 
that umbilical cord blood lead concentrations 
are generally lower than maternal blood lead 
concentrations (Chuang et al. 2001; Harville 
et al. 2005; Rothenberg et al. 1996). In > 500 
mother–infant pairs, the ratio of mean cord 
blood lead to mean maternal blood lead was 
0.78 (Chuang et al. 2001). Assuming that 
this ratio holds in the present study, the geo-
metric mean and 75th percentile of maternal 
blood lead would be approximately 0.86 and 
1.24 µg/dL, respectively. These estimates for 
maternal venous blood in the present study are 
lower than concurrent estimates among adult 
women in the National Health and Nutrition 
Examination Survey, where geometric mean 
and 75th percentile were 1.22 and 1.80 µg/dL 
in 2003–2004 and 1.11 and 1.73 µg/dL in 
2005–2006 (CDC 2010).
Bone lead is considered to be a better 
marker of long-term lead exposure, and blood 
lead a more precise estimate of short-term 
lead exposure (Hu et al. 2007). However, 
during pregnancy there is potentially a greater 
release of lead from bone into blood (Gulson 
et al. 1997), and maternal blood may be 
derived from mobilization of lead in bone. 
Nevertheless, if the mechanism(s) by which 
lead affects maternal blood pressure levels is 
heavily influenced by long-term lead expo-
sure, bone lead could be a better biomarker 
for describing a relationship of lead exposure 
with blood pressure. Rothenberg et al. (2002) 
found associations of maternal hypertension 
and elevations in blood pressure levels with 
maternal bone (calcaneous) lead but not with 
maternal venous blood lead. On the other 
hand, short-term or transient lead effects on 
Table 2. Change in blood pressure (mmHg) by quartiles of cord blood lead exposure based on multi-
variable regression models: Baltimore THREE Study, 2004–2005 (n = 285).
Parameter First quartile Second quartile Third quartile Fourth quartile p‑Trend
n 72 72 71 70
Lead (μg/dL) ≤ 0.46 0.47–0.65 0.66–0.95 ≥ 0.96
Admission 
SBP Referent 2.89 (–2.16 to 7.94) 1.05 (–4.04 to 6.14) 6.87 (1.51 to 12.21)* 0.033*
DBP Referent 0.00 (–3.95 to 3.96) 0.81 (–3.17 to 4.80) 4.40 (0.21 to 8.59)* 0.036*
Maximum
SBP Referent 2.47 (–3.08 to 8.02) –1.76 (–7.36 to 3.85) 7.72 (1.83 to 13.60)* 0.055
DBP Referent 3.93 (–2.86 to 10.72) –0.42 (–7.27 to 6.43) 8.33 (1.14 to 15.53)* 0.086
Multivariable linear regression models were controlled for maternal age, maternal race, neighborhood median 
  household income, primaparity, smoking during pregnancy, prepregnancy BMI, and anemia. p-Trend is based on a 
quartile model.
*p < 0.05.
Table 3. BMD values for umbilical cord blood lead (μg/dL) and maternal blood pressure, comparing Hill, 
linear, polynomial, and power models.
Measurement Hill Linear Polynomial Power
Admission SBP
BMD 1.50 2.57 0.22 1.46
BMDL 1.42 1.57 0.07 1.42
AIC 1,840 1,838 1,840 1,838
Admission DBP
BMD NC 2.71 NC 1.91
BMDL NC 1.62 NC 1.43
AIC NC 1,698 NC 1,699
Maximum SBP
BMD 1.46 2.50 0.15 1.45
BMDL 1.41 1.55 0.06 1.41
AIC 1,895 1,897 1,895 1,893
Maximum DBP
BMD 1.50 2.95 0.15 1.47
BMDL 1.43 1.71 0.06 1.43
AIC 2,009 2,009 2,009 2,007
NC, no calculation. BMD values were generated with Benchmark Dose Software using the geometric mean for umbili-
cal cord blood and adjusted maternal blood pressure (derived from models presented in Table 2) for each lead quartile. 
Average SDs for blood pressure were 15.1 mmHg (SBP admission), 11.9 mmHg (DBP admission), 16.7 mmHg (SBP maxi-
mum), and 20.4 mmHg (DBP maximum). The AIC is a unitless measure of model fit.Wells et al.
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blood pressure might be better assessed with 
biomarkers of recent lead dose such as blood 
lead (Navas-Acien et al. 2008). Knowledge 
of the mechanism by which lead exerts effects 
on blood pressure would be helpful in deter-
mining whether blood or bone lead is a bet-
ter biomarker for studying this relationship; 
although mechanisms have been suggested 
(Vaziri 2008), more work is ongoing.
Although maternal venous and umbilical 
cord blood lead are highly correlated, this 
correlation is not equivalent. If factors influ-
encing the ratio of maternal blood lead to 
cord blood were not related to blood pressure, 
this would result in random misclassifica-
tion of exposure, and as a result, our findings 
would be biased toward the null. In contrast, 
Harville et al. (2005) reported that higher 
maternal blood pressure is related to a lower 
ratio of maternal blood lead to cord blood 
lead; in that situation, our results could have 
been biased away from the null. However, 
evidence supporting this conclusion is some-
what limited because Harville et al. (2005) 
observed this relationship only in the subset of 
women > 30 years of age or with > 40 pounds 
of weight gain. Meanwhile, our findings are 
consistent with prospective evidence among 
nonpregnant adults, where placental transfer 
of lead would not influence results (Glenn 
et al. 2003), providing additional support for 
an association between lead exposure and sub-
sequent elevations in blood pressure.
Prior work has evaluated the influence of 
measurements of hematocrit or hemoglobin, 
stress, calcium, or zinc on the relationship 
between lead exposure and blood pressure lev-
els (Hense et al. 1993; Nawrot et al. 2002; 
Peters et al. 2007; Rabinowitz et al. 1987; 
Rothenberg et al. 1999). These data were not 
available for this study. Although hematocrit 
and hemoglobin have been associated with 
low lead concentrations (Harville et al. 2005), 
their role as a confounders has been proposed 
to be more important among older women 
(> 50 years) (Hense et al. 1993). Moreover, 
the association between blood lead levels and 
GH was only slightly decreased and remained 
statistically significant after further adjustment 
for hematocrit in a study during the third tri-
mester of pregnancy (Magri et al. 2003). Stress 
has been identified as an effect modifier of the 
lead–blood pressure relationship; those with 
higher stress had a higher risk of developing 
hypertension after lead exposure (Peters et al. 
2007). The observation that women in our 
population with higher cord blood leads had 
higher maximum blood pressure levels during 
labor and delivery is consistent with that work.
Our BMD analysis of these data pro-
vides a different perspective of the relation-
ship we observed between lead exposure and 
blood pressure increase. In terms of estimated 
maternal blood lead levels from cord blood 
levels (calculated as described above), we 
found a BMDL of roughly 1.4 µg/dL venous 
blood lead for all blood pressure outcomes. 
The BMDL, again, is an exposure level that, 
with 95% confidence, corresponds to the pre-
specified response (1 SD of blood pressure) 
(Sand et al. 2008). Although BMD analysis 
is frequently used in the process of creating 
regulatory exposure standards, our use of it 
here should not be interpreted in a regula-
tory context, but rather as a description of an 
exposure level in this study where we observed 
measurable effects.
No threshold effect of lead has been iden-
tified. Action levels for lead are based in part 
on our ability to create and invest in effective 
interventions for lead exposure, while recog-
nizing that the goal is to reduce exposures to 
the greatest extent possible (Bernard 2003). 
There is initial evidence that calcium supple-
mentation may be related to lower blood lead 
levels in pregnancy by reducing the release 
of lead from bone lead stores (Ettinger et al. 
2009), although this needs replication. Better 
still would be primary prevention, or pre-
venting lead exposure in the first place; this 
could occur, for example, by limiting the 
amount of lead released to the environment 
by implementing safer work practices (U.S. 
EPA 2010).
In this work, we show that the previously 
established association of blood lead levels with 
elevations in blood pressure can be replicated 
among pregnant women at the time of labor 
and delivery, extending previous findings to 
even lower lead exposure levels. Because even 
small reductions in population blood pressure 
could result in substantial public health ben-
efits (Whelton et al. 2002), this work suggests 
that continued reductions in lead exposure 
remain an important public health goal.
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